BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22329763)

  • 1. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
    Maier PS; Mattiello SS; Lages L; Spritzer PM
    Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
    Maier PS; Spritzer PM
    Gynecol Obstet Invest; 2012; 74(2):136-42. PubMed ID: 22889864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS).
    Marioli DJ; Saltamavros AD; Vervita V; Koika V; Adonakis G; Decavalas G; Markou KB; Georgopoulos NA
    Fertil Steril; 2009 Aug; 92(2):648-52. PubMed ID: 18692800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
    Bhattacharya SM; Jha A
    Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome.
    Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
    Acta Obstet Gynecol Scand; 1985; 64(3):195-202. PubMed ID: 3160211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
    Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
    Guido M; Romualdi D; Campagna G; Ricciardi L; Bompiani A; Lanzone A
    Reprod Sci; 2010 Aug; 17(8):767-75. PubMed ID: 20595709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term treatment of hirsutism related to micropolycystic ovary syndrome with a combination type oral contraceptive containing desogestrel.
    Sobbrio GA; Granata A; D'Arrigo F; Arena D; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1989; 20(1):35-7. PubMed ID: 2528880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
    Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
    Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of the HSD17B6 and HSD17B5 genes in Chinese women with polycystic ovary syndrome.
    Ke L; Che YN; Cao YX; Wu XK; Hu YL; Sun HX; Liang FJ; Sun J; Yi L; Wang Y
    J Womens Health (Larchmt); 2010 Dec; 19(12):2227-32. PubMed ID: 21039282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A; Cinar N; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in plasma levels of androgens and SHBG in patients with polycystic ovary syndrome (PCOs) treated with oral contraceptives containing desogestrel].
    Negri P; D'Errico G; Minisci N; Tomasi A
    Minerva Ginecol; 1988 Dec; 40(12):699-707. PubMed ID: 2977429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P; Agnello G; Borghesani F; Tomain L; Minisci N; D'Errico G; Cavallini AR
    Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.